drugset / Trial / NCT01289431

Mapracorat Ophthalmic Formulation in Subjects With Allergic Conjunctivitis

NCT01289431

Phase 2 Completed 236 enrolled Bausch & Lomb Incorporated
RandomizedParallel-groupDouble-blindPrevention

Summary

The objective of this study is to evaluate the dose response, and efficacy of Mapracorat ophthalmic formulation compared to its vehicle for the prevention of symptoms and signs associated with allergic conjunctivitis using a conjunctival allergen challenge (CAC) model.

Timeline

Start
2011-02
Primary completion
2011-04
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Mapracorat Small molecule Other

Indications